184 related articles for article (PubMed ID: 17323056)
1. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin).
Tennvall J; Fischer M; Bischof Delaloye A; Bombardieri E; Bodei L; Giammarile F; Lassmann M; Oyen W; Brans B; ; ;
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):616-22. PubMed ID: 17323056
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Wiseman GA; White CA; Sparks RB; Erwin WD; Podoloff DA; Lamonica D; Bartlett NL; Parker JA; Dunn WL; Spies SM; Belanger R; Witzig TE; Leigh BR
Crit Rev Oncol Hematol; 2001; 39(1-2):181-94. PubMed ID: 11418315
[TBL] [Abstract][Full Text] [Related]
3. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
Marcus R
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
[TBL] [Abstract][Full Text] [Related]
4. Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Zimmer AM
Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):14-9. PubMed ID: 14762740
[TBL] [Abstract][Full Text] [Related]
5. 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma.
Grillo-López AJ
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S44-9. PubMed ID: 15786025
[TBL] [Abstract][Full Text] [Related]
6. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma.
Witzig TE
Semin Oncol; 2000 Dec; 27(6 Suppl 12):74-8. PubMed ID: 11226003
[TBL] [Abstract][Full Text] [Related]
7. Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop.
Zinzani PL; d'Amore F; Bombardieri E; Brammer C; Codina JG; Illidge T; Jurczak W; Linkesch W; Morschhauser F; Vandenberghe E; Van Hoof A
Eur J Cancer; 2008 Feb; 44(3):366-73. PubMed ID: 18194857
[TBL] [Abstract][Full Text] [Related]
8. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE
J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
10. 90Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
Fink-Bennett DM; Thomas K
J Nucl Med Technol; 2003 Jun; 31(2):61-8; quiz 69-70. PubMed ID: 12777454
[TBL] [Abstract][Full Text] [Related]
11. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
Wiseman GA; Witzig TE
Cancer Biother Radiopharm; 2005 Apr; 20(2):185-8. PubMed ID: 15869453
[TBL] [Abstract][Full Text] [Related]
12. [Assessment for the image interpretation of 111In-ibritumomab tiuxetan in the phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma].
Oriuchi N; Koizumi K; Koizumi M; Terui S; Yamaura H; Imai Y; Kaneta T; Nawano S; Kubo A; Nishimura T; Kinuya S; Tobinai K; Endo K
Kaku Igaku; 2008 May; 45(2):99-113. PubMed ID: 19591405
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy for non-Hodgkin's lymphoma: a review for radiation oncologists.
Macklis RM; Pohlman B
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):833-41. PubMed ID: 16965871
[TBL] [Abstract][Full Text] [Related]
14. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
15. Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.
Weigert O; Illidge T; Hiddemann W; Dreyling M
Cancer; 2006 Aug; 107(4):686-95. PubMed ID: 16826593
[TBL] [Abstract][Full Text] [Related]
16. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.
Witzig TE; White CA; Gordon LI; Wiseman GA; Emmanouilides C; Murray JL; Lister J; Multani PS
J Clin Oncol; 2003 Apr; 21(7):1263-70. PubMed ID: 12663713
[TBL] [Abstract][Full Text] [Related]
17. Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma.
Tobinai K; Watanabe T; Ogura M; Morishima Y; Hotta T; Ishizawa K; Itoh K; Okamoto S; Taniwaki M; Tsukamoto N; Okumura H; Terauchi T; Nawano S; Matsusako M; Matsuno Y; Nakamura S; Mori S; Ohashi Y; Hayashi M; Endo K
Cancer Sci; 2009 Jan; 100(1):158-64. PubMed ID: 19018755
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice.
Jacene HA; Filice R; Kasecamp W; Wahl RL
J Nucl Med; 2007 Nov; 48(11):1767-76. PubMed ID: 17942813
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic imaging prior to 90Y-ibritumomab tiuxetan (Zevalin) treatment in follicular non-Hodgkin's lymphoma.
Otte A
Hell J Nucl Med; 2008; 11(1):12-5. PubMed ID: 18392220
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]